YOLFTbeta
Xintela AB

Xintela AB

XINT · ST · Healthcare / Biotechnology

0.14SEK+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.14
Open0.144
Day Range0.14 – 0.1495
52-Week Range0.15 – 0.497
Volume52.30K
Market Cap137.80M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.06
Dividend Yield0.00%
Beta1.91
50-Day Avg0.1747
200-Day Avg0.2308

About

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome; and EQSTEM that is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG10, which are in preclinical study for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. It has an agreement with Region Östergötland for GMP process development of cell therapy for burn patients. Xintela AB (publ) was incorporated in 2009 and is based in Lund, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Evy Lundgren-Åkerlund Assoc.Prof, BSc, Ph.D.
  • Employees11
  • HeadquartersMedicon Village, Lund, Sweden, 223 81, Sweden
  • Websitehttps://www.xintela.se

Leadership

  • Dr. Evy Lundgren-Åkerlund Assoc.Prof, BSc, Ph.D.Chief Executive Officer · b. 1957
  • Mr. Gunnar TelhammarCFO & Finance Director · b. 1961
  • Ms. Lucienne VonkChief Scientific Officer

Financials

Income Statement

Currency: SEK2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-10.03K757.00K3.00K2.00K1.63M38.00K00078.00K4.21M2.28M
Growth (%)--+7448.86%-99.60%-33.33%+81300.00%-97.67%-100.00%---+5303.85%-45.86%
Cost of Revenue--4.45M443.00K556.00K673.00K0-5.64M3.57M3.50M3.79M3.77M851.00K606.00K
Gross Profit-4.46M314.00K-553.00K-671.00K1.63M5.68M-3.57M-3.50M-3.79M78.00K4.21M1.68M
Gross Margin-44455.60%41.48%-18433.33%-33550.00%100.00%14944.74%---100.00%100.00%73.44%
Operating Expense-7.45M11.83M16.54M21.26M25.83M43.73M30.33M40.06M65.28M57.32M43.66M48.36M
Operating Income-2.24M-2.99M-11.51M-17.10M-21.93M-24.20M-38.05M-33.90M-43.56M-69.06M-57.24M-39.45M-46.68M
Operating Margin--29852.11%-1521.00%-569900.00%-1096650.00%-1486.73%-100123.68%----73382.05%-935.87%-2045.75%
EBITDA-2.22M-7.38M-11.07M-16.54M-21.26M-22.10M-33.92M-30.33M-57.11M-65.28M-53.47M-38.90M-46.08M
EBITDA Margin--73613.88%-1462.48%-551366.67%-1063000.00%-1357.74%-89252.63%----68552.56%-922.78%-2019.19%
Net Income-2.28M-3.01M-11.56M-18.06M-21.95M-26.27M-43.55M-52.92M-58.93M-66.22M-54.08M-39.19M-48.56M
Net Income Margin--29992.53%-1526.95%-602000.00%-1097250.00%-1613.88%-114600.00%----69337.18%-929.77%-2128.13%
R&D-6.34M8.58M14.53M16.22M17.64M34.71M38.17M44.12M55.79M46.24M33.22M35.95M
R&D as % of Total Revenue-63232.95%1133.29%484400.00%810800.00%1083.35%91352.63%---59280.77%788.16%1575.50%
Interest Expense015.00K45.00K963.00K12.00K2.07M18.00K2.67M538.00K4.11M1.14M2.11M3.49M
Interest Expense % of Total Revenue-149.58%5.94%32100.00%600.00%127.15%47.37%---1455.13%50.13%152.80%

Balance Sheet

Currency: SEK2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets7.08M10.50M10.62M23.85M28.59M49.71M17.09M48.51M24.74M24.52M18.39M24.80M29.02M
Total Liabilities2.00M954.29K3.16M2.87M10.17M4.77M7.77M20.91M20.80M18.74M14.02M30.75M34.30M
Total Equity5.08M9.54M7.46M20.98M18.41M44.95M9.32M27.61M3.95M5.78M4.38M-5.95M-5.27M
Cash2.37M823.79K5.52M18.98M21.91M31.40M412.00K33.60M9.94M8.34M7.81M16.68M23.21M
Total Debt-------10.90M----20.00M
Net Debt-2.37M-823.79K-5.52M-18.98M-21.91M-31.40M-412.00K-22.70M-9.94M-8.34M-7.81M-16.68M-3.21M

Cash Flow

Currency: SEK2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.01M-4.15M-9.54M-17.40M-14.37M-31.20M-30.89M-21.33M-42.89M-39.49M-53.12M-40.70M-41.62M
Investing Cash Flow-640.00K-4.87M-898.00K-725.00K-2.07M-12.11M-2.53M-329.00K-1.20M-27.52M-104.00K00
Financing Cash Flow6.01M7.47M15.13M31.58M19.38M52.80M2.44M54.85M20.43M64.56M51.79M50.09M48.53M
Capital Expenditure093.00K898.00K725.00K2.07M12.25M1.62M383.00K1.25M111.00K104.00K041.62M
Free Cash Flow-3.01M-4.24M-10.43M-18.13M-16.45M-43.45M-32.51M-21.71M-44.15M-39.60M-53.22M-40.70M-41.62M
FCF to OCF100.00%102.24%109.42%104.17%114.43%139.24%105.24%101.80%102.93%100.28%100.20%100.00%100.00%

Earnings

Report DateMar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Aug 28, 2020Nov 27, 2020Feb 26, 2021Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Nov 29, 2023Feb 28, 2024May 8, 2024Aug 30, 2024Nov 25, 2024Feb 28, 2025May 8, 2025Aug 29, 2025Nov 5, 2025Feb 27, 2026May 29, 2026Aug 28, 2026
EPS Estimate------------------------------------------
EPS Actual-0.11-0.12-0.07-0.12-0.12-0.10-0.10-0.13-0.14-0.10-0.08-0.15-0.13-0.15-0.11-0.21-0.10-0.22-0.14-0.34-0.07-0.08-0.07-0.18-0.11-0.21-0.11-0.09-0.05-0.06-0.02-0.03-0.02-0.02-0.01-0.02-0.02-0.02-0.01-0.02-0.01-0.01
Surprise------------------------------------------
Timing--------------------------------Pre-market---Pre-market-----

Key Statistics & Ratios

Market Cap137.80M
Enterprise Value146.55M
Trailing P/E0.00
Forward P/E0.00
Price / Sales45.49
Price / Book35.21
EPS-0.06
Book Value-0.02
Revenue (TTM)3.03M
Gross Profit (TTM)3.03M
EBITDA-45.42M
Profit Margin0.00%
Operating Margin-735.16%
Return on Equity-1064.94%
Return on Assets-107.70%
Shares Outstanding861.27M
Shares Float402.52M
Beta1.91
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%